R C Moellering

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi Antimicrobial resistance prevention initiative--an update: proceedings of an expert panel on resistance
    Robert C Moellering
    Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Am J Med 120:S4-25; quiz S26-8. 2007
  2. ncbi The continuing challenge of lower respiratory tract infections
    Robert C Moellering
    Dept of Medicine, Harvard Medical School and Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Clin Infect Dis 38:S319-21. 2004
  3. ncbi Vancomycin: a 50-year reassessment
    Robert C Moellering
    Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Clin Infect Dis 42:S3-4. 2006
  4. ncbi The management of infections due to drug-resistant gram-positive bacteria
    R C Moellering
    Department of Medicine, Beth Israel Deaconess Medical Center, 110 Francis Street, Suite 6A, Boston, MA 02215, USA
    Eur J Clin Microbiol Infect Dis 24:777-9. 2005
  5. ncbi Antimicrobial resistance prevention initiative--an update: proceedings of an expert panel on resistance
    Robert C Moellering
    Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Am J Infect Control 35:S1-23; quiz S24-6. 2007
  6. ncbi A 39-year-old man with a skin infection
    Robert C Moellering
    Beth Israel Deaconess Medical Center, Department of Medicine, 110 Francis St, Ste 6A, Boston, MA 02215
    JAMA 299:79-87. 2008
  7. doi Current treatment options for community-acquired methicillin-resistant Staphylococcus aureus infection
    Robert C Moellering
    Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    Clin Infect Dis 46:1032-7. 2008
  8. doi MRSA: the first half century
    Robert C Moellering
    Harvard Medical School and Beth Israel Deaconess Medical Center, Boston, MA, USA
    J Antimicrob Chemother 67:4-11. 2012
  9. doi Discovering new antimicrobial agents
    Robert C Moellering
    Harvard Medical School and Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Int J Antimicrob Agents 37:2-9. 2011
  10. doi Advances in antibacterial therapy
    R C Moellering
    Department of Medicine, Harvard Medical School and Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Transplant Proc 43:2441-2. 2011

Detail Information

Publications59

  1. ncbi Antimicrobial resistance prevention initiative--an update: proceedings of an expert panel on resistance
    Robert C Moellering
    Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Am J Med 120:S4-25; quiz S26-8. 2007
    ..The challenges in each area are different, but the general keys to addressing the growing problem of antimicrobial resistance continue to be responsible antimicrobial stewardship and the development of newer antimicrobial agents...
  2. ncbi The continuing challenge of lower respiratory tract infections
    Robert C Moellering
    Dept of Medicine, Harvard Medical School and Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Clin Infect Dis 38:S319-21. 2004
  3. ncbi Vancomycin: a 50-year reassessment
    Robert C Moellering
    Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Clin Infect Dis 42:S3-4. 2006
  4. ncbi The management of infections due to drug-resistant gram-positive bacteria
    R C Moellering
    Department of Medicine, Beth Israel Deaconess Medical Center, 110 Francis Street, Suite 6A, Boston, MA 02215, USA
    Eur J Clin Microbiol Infect Dis 24:777-9. 2005
  5. ncbi Antimicrobial resistance prevention initiative--an update: proceedings of an expert panel on resistance
    Robert C Moellering
    Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Am J Infect Control 35:S1-23; quiz S24-6. 2007
    ..The challenges in each area are different, but the general keys to addressing the growing problem of antimicrobial resistance continue to be responsible antimicrobial stewardship and the development of newer antimicrobial agents...
  6. ncbi A 39-year-old man with a skin infection
    Robert C Moellering
    Beth Israel Deaconess Medical Center, Department of Medicine, 110 Francis St, Ste 6A, Boston, MA 02215
    JAMA 299:79-87. 2008
    ..For more serious, life-threatening infections, linezolid or parenteral agents such as vancomycin or daptomycin should be considered...
  7. doi Current treatment options for community-acquired methicillin-resistant Staphylococcus aureus infection
    Robert C Moellering
    Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    Clin Infect Dis 46:1032-7. 2008
    ....
  8. doi MRSA: the first half century
    Robert C Moellering
    Harvard Medical School and Beth Israel Deaconess Medical Center, Boston, MA, USA
    J Antimicrob Chemother 67:4-11. 2012
    ..In a very real sense, this year marks the 'birthday' of a remarkably successful pathogen. The major reasons for the ability of MRSA to prosper and cause disease in settings inimical to its survival form the basis of this article...
  9. doi Discovering new antimicrobial agents
    Robert C Moellering
    Harvard Medical School and Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Int J Antimicrob Agents 37:2-9. 2011
    ..Given the amount of investigation presently underway, it is clear that although the antibiotic pipeline is not as promising as it was half a century ago, it is far from dry...
  10. doi Advances in antibacterial therapy
    R C Moellering
    Department of Medicine, Harvard Medical School and Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Transplant Proc 43:2441-2. 2011
    ..This article reviews the potential role of some antibiotics recently marketed or in clinical development, with a focus on their potential use in transplant recipients...
  11. doi The problem of complicated skin and skin structure infections: the need for new agents
    Robert C Moellering
    Harvard Medical School and Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    J Antimicrob Chemother 65:iv3-8. 2010
    ..The papers included provide data on the in vitro activity, pharmacokinetics and pharmacodynamics as well as the clinical efficacy of ceftaroline fosamil, which is a welcome addition to our therapeutic armamentarium against cSSSIs...
  12. ncbi Prolonged colonization with vancomycin-resistant Enterococcus faecium in long-term care patients and the significance of "clearance"
    L R Baden
    Division of Infectious Disease, Beth Israel Deaconess Medical Center, Boston, MA 02115, USA
    Clin Infect Dis 33:1654-60. 2001
    ..Cultures for detection of VRE in stool samples obtained from patients declared "cleared" are insensitive...
  13. pmc Diversity of domain V of 23S rRNA gene sequence in different Enterococcus species
    S Tsiodras
    Department of Medicine, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, Massachusetts 02215, USA
    J Clin Microbiol 38:3991-3. 2000
    ..malodoratus by 2 bases. E. avium differed from E. raffinosus by one base. Despite the fact that domain V is considered to be highly conserved, substantial differences were identified between several enterococcal species...
  14. pmc Characterization of vancomycin-resistant Enterococcus faecium isolates from the United States and their susceptibility in vitro to dalfopristin-quinupristin
    G M Eliopoulos
    Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Antimicrob Agents Chemother 42:1088-92. 1998
    ..Multiple drug resistance was very common among these isolates of vancomycin-resistant E. faecium, while dalfopristin-quinupristin inhibited the majority at concentrations that are likely to be clinically relevant...
  15. pmc Prevalence of the fsr locus in Enterococcus faecalis infections
    S K Pillai
    Division of Infectious Diseases, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02115, USA
    J Clin Microbiol 40:2651-2. 2002
    ..faecalis clinical isolates demonstrated fsr in all endocarditis isolates versus 53% of stool isolates (P = 0.005). This supports a role for fsr-mediated virulence in the pathogenesis of enterococcal infections in humans...
  16. ncbi Staphylococcus aureus accessory gene regulator (agr) group II: is there a relationship to the development of intermediate-level glycopeptide resistance?
    George Sakoulas
    Department of Medicine, Division of Laboratory and Transfusion Medicine and Harvard Medical School, Boston, Massachussetts, USA
    J Infect Dis 187:929-38. 2003
    ..This study suggests that some S. aureus strains have an intrinsic survival advantage under a glycopeptide selective pressure, which is possibly related to reduced autolysis after exposure to subinhibitory concentrations of glycopeptide...
  17. pmc In vitro activity of an oral streptogramin antimicrobial, XRP2868, against gram-positive bacteria
    G M Eliopoulos
    Department of Medicine, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, Massachusetts 02215, USA
    Antimicrob Agents Chemother 49:3034-9. 2005
    ..25 microg/ml and was fourfold more potent than quinupristin-dalfopristin against Staphylococcus aureus and Enterococcus faecium...
  18. pmc Molecular characterization of vancomycin-resistant Enterococci repopulating the gastrointestinal tract following treatment with a novel glycolipodepsipeptide, ramoplanin
    L R Baden
    Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA
    J Clin Microbiol 40:1160-3. 2002
    ..8; P = 0.004), and the avoidance of such antibiotics was significantly associated with culture negativity through day 21 (RR = 0.16; P = 0.02)...
  19. ncbi Clinical and public health implications of macrolide-resistant Streptococcus pneumoniae
    R C Moellering
    Beth Israel Deaconess Medical Center, Department of Medicine, Boston, MA 02215, USA
    J Chemother 14:42-56. 2002
    ..Further studies are required to monitor and control macrolide resistance and evaluate settings in which macrolide treatment failures are occurring, and new therapeutic interventions are needed...
  20. pmc Activity of fleroxacin alone and in combination with clindamycin or metronidazole in experimental intra-abdominal abscesses
    A Pefanis
    Department of Medicine, New England Deaconess Hospital, Boston, MA 02215
    Antimicrob Agents Chemother 38:252-5. 1994
    ..These results suggest that the addition of either metronidazole or clindamycin would effectively enhance the spectrum of fleroxacin for treatment of mixed aerobic and anaerobic infections...
  21. doi Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains
    George Sakoulas
    Division of Infectious Diseases, Department of Medicine, Westchester Medical Center and New York Medical College, Valhalla, New York, USA
    Clin Infect Dis 46:S360-7. 2008
    ..aureus. Therefore, it appears that our definition of vancomycin susceptibility requires further scrutiny as applied to serious MRSA infections, such as bacteremia and pneumonia...
  22. pmc Evaluation of endocarditis caused by methicillin-susceptible Staphylococcus aureus developing nonsusceptibility to daptomycin
    George Sakoulas
    Department of Medicine, Division of Infectious Diseases, New York Medical College, Munger Pavilion, Room 245, Valhalla, NY 10595, USA
    J Clin Microbiol 46:220-4. 2008
    ..Early surgical intervention or combination therapy or both might have prevented the loss of daptomycin susceptibility...
  23. ncbi Chloramphenicol treatment for vancomycin-resistant Enterococcus faecium bacteremia
    J C Ricaurte
    Section of Infectious Diseases, Department of Medicine, Saint Vincent's Hospital and Medical Center of New York 10011, USA
    Clin Microbiol Infect 7:17-21. 2001
    ..The use of chloramphenicol should be considered in treating infections with this highly resistant organism, where therapeutic options are limited...
  24. pmc In vitro activity of the new oxazolidinone AZD2563 against Enterococci
    G M Eliopoulos
    Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02115, USA
    Antimicrob Agents Chemother 46:3273-5. 2002
    ..In most cases, AZD2563 was twofold more active than linezolid against enterococci...
  25. ncbi Linezolid resistance in sequential Staphylococcus aureus isolates associated with a T2500A mutation in the 23S rRNA gene and loss of a single copy of rRNA
    Venkata G Meka
    Division of Infectious Diseases, Department of Medicine, and Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    J Infect Dis 190:311-7. 2004
    ..The most recent isolate of this series was recovered 7 months after the patient discontinued linezolid and demonstrated reversion to a susceptible phenotype associated with a loss of the T2500A mutation...
  26. ncbi Linezolid resistance in Staphylococcus aureus: characterization and stability of resistant phenotype
    Satish K Pillai
    Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02115, USA
    J Infect Dis 186:1603-7. 2002
    ..Compared with 2 linezolid-susceptible S. aureus isolates, the linezolid-resistant S. aureus isolate demonstrated no significant differences in in vitro growth characteristics...
  27. pmc Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin
    George Sakoulas
    Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02115, USA
    Antimicrob Agents Chemother 46:1492-502. 2002
    ..These findings imply that compromised agr function is advantageous to clinical isolates of S. aureus toward the development of vancomycin heteroresistance, perhaps through the development of vancomycin tolerance...
  28. pmc Reduced susceptibility to vancomycin influences pathogenicity in Staphylococcus aureus infection
    Anton Y Peleg
    Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Massachusetts General Hospital, and Harvard Medical School, Boston, MA 02215, USA
    J Infect Dis 199:532-6. 2009
    ..These results show that G. mellonella can be effectively used to facilitate the in vivo study of S. aureus virulence and, more specifically, the relationship between antibiotic drug resistance and the pathogenesis of infection...
  29. pmc Galleria mellonella as a model system to study Acinetobacter baumannii pathogenesis and therapeutics
    Anton Y Peleg
    Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
    Antimicrob Agents Chemother 53:2605-9. 2009
    ..G. mellonella is a relatively simple, nonmammalian model system that can be used to facilitate the in vivo study of host-pathogen interactions in A. baumannii and the efficacy of antibacterial agents...
  30. doi Development of reduced vancomycin susceptibility in methicillin-susceptible Staphylococcus aureus
    Satish K Pillai
    Division of Infectious Diseases, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, Massachusetts 02215, USA
    Clin Infect Dis 49:1169-74. 2009
    ..aureus (MSSA) clinical isolates. This isogenic series permitted us to determine whether the evolution of reduced vancomycin susceptibility in MSSA is similar to that seen in MRSA...
  31. pmc Lack of bactericidal antagonism or synergism in vitro between oxacillin and vancomycin against methicillin-susceptible strains of Staphylococcus aureus
    Christian Joukhadar
    Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA
    Antimicrob Agents Chemother 54:773-7. 2010
    ..Using these methods, we found no evidence that vancomycin antagonized the bactericidal effect of oxacillin or that there was any benefit from use of the combination...
  32. ncbi Persistence of rRNA operon mutated copies and rapid re-emergence of linezolid resistance in Staphylococcus aureus
    Athanassios Tsakris
    Division of Infectious Diseases, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA 02115, USA
    J Antimicrob Chemother 60:649-51. 2007
    ....
  33. pmc Modeling the invasion of community-acquired methicillin-resistant Staphylococcus aureus into hospitals
    Erica M C D'Agata
    Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    Clin Infect Dis 48:274-84. 2009
    ..If true, this event would have serious consequences, because CA-MRSA infections in hospitals would occur among a more debilitated, older patient population...
  34. ncbi New approaches to developing antimicrobials for resistant bacteria
    Robert C Moellering
    Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    J Infect Chemother 9:8-11. 2003
  35. ncbi Reversion to susceptibility in a linezolid-resistant clinical isolate of Staphylococcus aureus
    Venkata G Meka
    Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Boston, MA 02115, USA
    J Antimicrob Chemother 54:818-20. 2004
    ..aureus isolate that developed linezolid resistance (MIC of linezolid of 12 mg/L) after a 25 day course of the drug. Sequencing identified G2576T mutations in four of the five copies of the 23S rRNA gene...
  36. ncbi Effects of glucose on fsr-mediated biofilm formation in Enterococcus faecalis
    Satish K Pillai
    Beth Israel Deaconess Medical Center, Boston, Massachusetts 02115, USA
    J Infect Dis 190:967-70. 2004
    ..The present study provides additional insight into the mechanisms used by E. faecalis to establish nosocomial infection...
  37. pmc Prokaryote-eukaryote interactions identified by using Caenorhabditis elegans
    Anton Y Peleg
    Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA 02114, USA
    Proc Natl Acad Sci U S A 105:14585-90. 2008
    ..elegans and by use of genetic manipulation, provides a whole-animal model system to investigate the complex dynamics of a polymicrobial infection...
  38. ncbi Linezolid: the first oxazolidinone antimicrobial
    Robert C Moellering
    Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Ann Intern Med 138:135-42. 2003
    ..The drug has an acceptable profile of adverse events, but reversible myelosuppression has occurred in patients receiving high doses for more than 2 weeks...
  39. pmc A gene conferring resistance to vancomycin but not teicoplanin in isolates of Enterococcus faecalis and Enterococcus faecium demonstrates homology with vanB, vanA, and vanC genes of enterococci
    H S Gold
    Department of Medicine, New England Deaconess Hospital, Boston, Massachusetts 02215
    Antimicrob Agents Chemother 37:1604-9. 1993
    ..Neither curing nor transfer of vancomycin resistance was consistently related to loss or acquisition, respectively, of plasmid DNA...
  40. pmc Utility of peptide nucleic acid fluorescence in situ hybridization for rapid detection of Acinetobacter spp. and Pseudomonas aeruginosa
    A Y Peleg
    Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    J Clin Microbiol 47:830-2. 2009
    ..and 100% and 95%, respectively, for P. aeruginosa. PNA FISH was able to detect both pathogens simultaneously and directly from spiked blood cultures...
  41. pmc Drug interactions modulate the potential for evolution of resistance
    Jean Baptiste Michel
    Department of Systems Biology, Harvard Medical School, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 105:14918-23. 2008
    ..This framework reveals the central role of drug epistasis in the evolution of resistance and points to new strategies for combating the emergence of drug-resistant bacteria...
  42. pmc Genetic diversity among Enterococcus faecalis
    Shonna M McBride
    Schepens Eye Research Institute, Harvard Medical School, Boston, Massachusetts, United States of America
    PLoS ONE 2:e582. 2007
    ..Comparing genomic hybridization profiles, using a microarray, of strains identified by MLST as spanning the diversity of the species, allowed us to identify the core E. faecalis genome as consisting of an estimated 2057 unique genes...
  43. pmc Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia
    George Sakoulas
    Crystal Run Healthcare, 155 Crystal Run Rd, Middletown, NY 10941, USA
    J Clin Microbiol 42:2398-402. 2004
    ..Prognostic information for vancomycin treatment outcome in MRSA bacteremia may also be obtained by testing the in vitro bactericidal potency of vancomycin...
  44. ncbi Adaptation of methicillin-resistant Staphylococcus aureus in the face of vancomycin therapy
    George Sakoulas
    Westchester Medical Center, Division of Infectious Diseases, New York Medical College, Valhalla, NY 10595, USA
    Clin Infect Dis 42:S40-50. 2006
    ..aureus might, in part, explain the decreased efficacy of vancomycin in the therapy of methicillin-resistant S. aureus bacteremia, thus highlighting the need to reevaluate the criteria of susceptibility to vancomycin...
  45. pmc Reduced susceptibility of Staphylococcus aureus to vancomycin and platelet microbicidal protein correlates with defective autolysis and loss of accessory gene regulator (agr) function
    George Sakoulas
    Westchester Medical Center, New York Medical College, Valhalla, New York 10595, USA
    Antimicrob Agents Chemother 49:2687-92. 2005
    ..In vitro, these events were associated with defective lysis and reduced susceptibility to tPMP. The precise mechanism(s) underlying these findings is the subject of current investigations...
  46. doi Clinical decisions. Management of skin and soft-tissue infection
    Henry F Chambers
    Wilmington Health Associates and the Department of Medicine, University of North Carolina School of Medicine, Wilmington, USA
    N Engl J Med 359:1063-7. 2008
  47. pmc Clinical rationale for treatment of endocarditis caused by methicillin-susceptible Staphylococcus aureus developing nonsusceptibility to daptomycin
    Zukile Gqada
    J Clin Microbiol 46:2471; author reply 2471-2. 2008
  48. pmc Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin
    George Sakoulas
    Division of Infectious Diseases, New York Medical College, Munger Pavilion, Room 245, Valhalla, NY 10595, USA
    Antimicrob Agents Chemother 50:1581-5. 2006
    ..aureus passaged in vancomycin-containing medium. A correlation between vancomycin and daptomycin heteroresistance was noted in some strains, suggesting that exposure of S. aureus to vancomycin may affect susceptibility to daptomycin...
  49. pmc Daptomycin nonsusceptibility in Staphylococcus aureus with reduced vancomycin susceptibility is independent of alterations in MprF
    Satish K Pillai
    Department of Infectious Disease, Cleveland Clinic Foundation, Mailstop S32, Cleveland, OH 44195, USA
    Antimicrob Agents Chemother 51:2223-5. 2007
    ..aureus isolates which developed vancomycin heteroresistance, as well as daptomycin nonsusceptibility despite a lack of exposure to this drug, there were no mutations resulting in amino acid substitutions in MprF...
  50. ncbi The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus
    Fred C Tenover
    Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    Clin Infect Dis 44:1208-15. 2007
    ..aureus. This decision reflected a growing amount of microbiological and clinical data indicating that isolates of S. aureus are less likely to respond to vancomycin therapy when the vancomycin MICs are > or = 4 microg/mL...
  51. ncbi Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy
    Pamela A Moise-Broder
    School of Pharmacy and Pharmaceutical Sciences, State University of New York at Buffalo, Buffalo, NY, USA
    Clin Infect Dis 38:1700-5. 2004
    ..aureus clones with this genetic marker under vancomycin selective pressure...
  52. ncbi Effects of prolonged vancomycin administration on methicillin-resistant Staphylococcus aureus (MRSA) in a patient with recurrent bacteraemia
    George Sakoulas
    Westchester Medical Center and New York Medical College, Valhalla, USA
    J Antimicrob Chemother 57:699-704. 2006
    ..To evaluate microbiological properties of methicillin-resistant Staphylococcus aureus (MRSA) during prolonged vancomycin therapy...
  53. ncbi Microbial resistance: bacteria and more
    Martin J Wood
    Department of Infection, Birmingham University, Heartlands Hospital, Birmingham, United Kingdom
    Clin Infect Dis 36:S2-3. 2003
  54. ncbi Introduction of erm(C) into a linezolid- and methicillin-resistant Staphylococcus aureus does not restore linezolid susceptibility
    George Sakoulas
    J Antimicrob Chemother 51:1039-41. 2003
  55. ncbi The growing menace of community-acquired methicillin-resistant Staphylococcus aureus
    Robert C Moellering
    Ann Intern Med 144:368-70. 2006
  56. ncbi The importance of bactericidal drugs: future directions in infectious disease
    Robert W Finberg
    University of Massachusetts Medical Center, Worcester, MA 01655, USA
    Clin Infect Dis 39:1314-20. 2004
    ..Although a considerable amount of research has gone into the study of the role of bactericidal versus bacteriostatic antimicrobial agents in the treatment of different infectious diseases, there is no accepted standard of practice...
  57. doi Telithromycin and the FDA: implications for the future
    David M Shlaes
    Lancet Infect Dis 8:83-5. 2008
  58. ncbi The United States Food and Drug Administration and the end of antibiotics
    David M Shlaes
    Clin Infect Dis 34:420-2. 2002
  59. ncbi Antimicrobial-associated acute hepatitis
    Susan C Nicholson
    Infectious Diseases, Bristol Myers Squibb, Plainsboro, New Jersey 08536, USA
    Pharmacotherapy 22:794-6; discussion 796-7. 2002
    ....